TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01472770
Drug: Gemcitabine + Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine: 1000 mg/m2 intravenously over 30 min. on day 1 in 2-weeks cycles. Capecitabine: Peroral tablet 2000 mg/m2 daily on days 1-7 in 2-weeks cycles.
Study: NCT04347915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo once a day for 14 days (up to 21 days)
Study: NCT01911442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01378039
Drug: comparison of treatment effect on different markers
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled budesonide (400 µg BD) or placebo BD
Study: NCT03893318
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT04119921
Drug: prescription artificial tear in group 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
Study: NCT03423680
Drug: Abilify 2, 5, 10, 15mg (Tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
Study: NCT04119921
Drug: prescription topical ketorolac in group 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
Study: NCT01119742
Drug: Vehicle A
Normalized name: Vehicle and emulsifier patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application for 7 days
Study: NCT01119742
Drug: Vehicle B
Normalized name: vehicle base no.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application for 7 days
Study: NCT04660461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
Study: NCT03423680
Drug: Placebo of Abilify 2, 5, 10, 15mg (Tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
Study: NCT03877562
Drug: CORT118335
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT118335 600 mg oral tablets administered as 2 X 300 mg or 6 X 100 mg tablets
Study: NCT03877562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching CORT118335, 2 or 6 oral tablets, depending on the CORT118335 tablet strength available
Study: NCT04119921
Drug: prescription artificial tear in group1
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
Study: NCT03678129
Drug: AZD7325_10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose (10mg)
Study: NCT03678129
Drug: AZD7325_20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose (20mg)
Study: NCT03678129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose placebo (capsule)
Study: NCT04659161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsules twice a day (BID)
Study: NCT02188303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01236573
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) over 1 hr.
Study: NCT02584439
Drug: lactose capsule (placebo)
Normalized name: lactose Oral Capsule
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
Study: NCT04433611
Drug: 0.9 % normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrauterine infusion of 0.9 % normal saline
Study: NCT02758691
Drug: Intranasal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants in the devise testing portion of the study will self-administer a 20 mL dose of intranasal saline. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 mL dose of intranasal saline.
Study: NCT02462317
Drug: Placebo toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injection
Study: NCT01004237
Drug: pravastatin, valsartan, pravastatin+valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 40 mg, valsartan 160 mg 8 weeks of treatment
Study: NCT02561793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: women will receive a placebo 12 weeks before starting IVF/ICSI
Study: NCT01659242
Drug: Methotrexate plus sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose.
Study: NCT01835015
Drug: CLG561
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravitreal injection, Day 1
Study: NCT00530114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
Study: NCT02134964
Drug: OLT1177 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLT1177 Capsules are an experimental drug.
Study: NCT02134964
Drug: Placebo Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
Study: NCT00492323
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily for 4 weeks
Study: NCT00630279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01606540
Drug: Tablets Ibumetin and placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after reposition.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after reposition. The following days placebo tablets.~Group C: Placebo tablets 1 week after reposition.
Study: NCT01606540
Drug: Tablets Ibumetin and placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after surgery.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after surgery. The following days placebo tablets.~Group C: Placebo tablets for 1 week after surgery.
Study: NCT00040482
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01765114
Drug: PEG-Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01893632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03533972
Drug: Ashwagandha
Normalized name: Ashwagandha
Approvals — FDA: no, EMA: no, PMDA: no
Description: ashwagandha capsules given to the subjects twice daily after meals for 1 month
Study: NCT01536574
Drug: Requip PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.
Study: NCT01605279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo (dextrose 5% in water, D5W, as Placebo)
Study: NCT02691975
Drug: SHR3680
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.
Study: NCT00834756
Drug: Azithromycin 600 mg Tablet
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 x 600mg, single-dose fasting
Study: NCT00834756
Drug: Zithromax® 600 mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 600mg, single-dose fasting
Study: NCT04239872
Drug: Calcium and fluoride mouthwash
Normalized name: sodium fluoride Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium lactate, at a concentration of 150 milimolar, will be used to rinse the mouth for 1 minute and expectorated; immediately after, a sodium fluoride rinse, at a concentration of 0.05% (226 ppm of fluoride), will be used to rinse the mouth for 1 minute, and expectorated.
Study: NCT01466868
Drug: MK2206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.~The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms.
Study: NCT02485769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension
Study: NCT02485769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (Modified Release)
Study: NCT03541941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered intraoperatively through a transversus abdominis plane (TAP) block
Study: NCT03880487
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose and Multiple dose identical to active treatment but without KP-1199.
Study: NCT03680911
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
Study: NCT01792635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.
Study: NCT03287310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.
Study: NCT00804674
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01517893
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
Study: NCT01517893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
Study: NCT02839265
Drug: FLT3 Ligand Therapy (CDX-301)
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Arm 1 descriptions
Study: NCT02591927
Drug: Glucose 5%
Normalized name: Glucose 5% Nursette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
Study: NCT00296647
Drug: patch + lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
Study: NCT01375257
Drug: Oral treatment with antibiotics for endocarditis
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02045550
Drug: Prospan Syrup
Normalized name: Irospan Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml twice daily for 4 weeks
Study: NCT01540760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching MCAF5352A, multiple doses
Study: NCT01375257
Drug: Guideline treatment with parenteral antibiotics
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02449265
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in both arms will be given cyclophpsphamide chemotherapy.
Study: NCT02449265
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in both arms will be given doxorubicin chemotherapy.
Study: NCT02133196
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.
Study: NCT03700320
Drug: Standard of Care (SOC) Migraine Preventive Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.
Study: NCT04080947
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received matching-image placebo once daily at bedtime for 12 weeks.
Study: NCT00956397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo TID x 10 days
Study: NCT02601677
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
Study: NCT02820155
Drug: RGN1016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
Study: NCT02820155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
Study: NCT02035085
Drug: CS-1000 labeled SVF cells
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo autologous transplantation of CS-1000 labelled SVF cells in a sterile environment.
Study: NCT04133623
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
Study: NCT04133623
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
Study: NCT00891982
Drug: CTGel/ BPO Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days~Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days.
Study: NCT00891982
Drug: Soap Free Cleanser and CTGel
Normalized name: Aqua Glycolic Shampoo and Body Cleanser Soap Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soap Free Cleanser will be used once daily in the morning for 28 days~Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days.
Study: NCT01991990
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. infusion
Study: NCT00003784
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003784
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003784
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03096730
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is intravenously administrated before anesthesia induction
Study: NCT03096730
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil is intravenously administrated
Study: NCT03096730
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil is intravenously administrated
Study: NCT00547170
Drug: Doxycycline pre-operatively
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)
Study: NCT00547170
Drug: Doxycycline post-operatively
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two capsules of placebo 100 mg before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)
Study: NCT02388191
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 550 mg, oral, on day 1. Number of Cycles: 1
Study: NCT00965185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00808171
Drug: Livopan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of oxygen and nitrous oxide 50%
Study: NCT00808171
Drug: Livopan
Approvals — FDA: no, EMA: no, PMDA: no
Description: equimolar mixture of N2O/O2
Study: NCT03966365
Drug: PRO-122
Approvals — FDA: no, EMA: no, PMDA: no
Description: * PRO-122. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution free of preservatives. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* Route of administration: topical ophthalmic.
Study: NCT03966365
Drug: Krytantek Ofteno®
Approvals — FDA: no, EMA: no, PMDA: no
Description: * - 1. Krytantek Ofteno®. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* - Route of administration: topical ophthalmic.
Study: NCT02139111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsule
Study: NCT02139111
Drug: PRC-063 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 25 mg capsule - active
Study: NCT01840735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02139111
Drug: PRC-063 45 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 45 mg capsule - active
Study: NCT02139111
Drug: PRC-063 70 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 70 mg capsule - active
Study: NCT02139111
Drug: PRC-063 85 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 85 mg capsule - active
Study: NCT01220362
Drug: Bupivacain 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacain 0.125%
Study: NCT01220362
Drug: Bupivacain 0.125%/Fentanyl 2mcg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacain 0.125%/Fentanyl 2mcg/ml
Study: NCT00520234
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 cc IV daily
Study: NCT03642548
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in control group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Placebo.
Study: NCT00881127
Drug: Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03600376
Drug: Ryanodex and Standard of Care
Normalized name: Ryanodex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ryanodex to be administered as a rapid IV push
Study: NCT02546570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm/group descriptions for dosage amount and procedure.
Study: NCT02496546
Drug: LEO 32731 cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied for 3 weeks
Study: NCT02496546
Drug: LEO 32731 cream vehicle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied for 3 weeks
Study: NCT04314505
Drug: Opioid-Based Patient Controlled Analgesia
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. The patient was informed that the intravenous bolus of rescue morphine (4mg) was available every 4 hours if the pain was intolerable. In the PCA group, the device was applied before incision and the initial setting was 0.01mg/kg\*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours. After the surgery, the staff of PCA group would visit the patients and adjusted the dosage. The PCA was removed after 72 hours from the surgery. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
Study: NCT01033305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, once per day for 4 weeks
Study: NCT04227509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline will be administered as a 30 minute IV infusion every 3 weeks.
Study: NCT04443543
Drug: Capecitabine (Xeloda) Pharmacogenetic Test Reagents
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CRT: 625mg/m2 bid Monday-Friday per week XELIRI: 1000mg/m2 bid d1-14
Study: NCT04443543
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FOLFIRINOX: 400mg/m2 iv d1bolus, 2400mg/m2 ivgtt 46h
Study: NCT02744820
Drug: GMC-252-L-Lysine Salt
Normalized name: Lysine acetylcysteinate salt
DrugBank: Nacystelyn (DB17839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose by oral route, once a day, 28 days